Marco Peters

US Patent:

7968524, Jun 28, 2011

Filed:

May 15, 2008

Appl. No.:

12/121731

Inventors:

Marco Peters - La Jolla CA, US
Roderick Euan Milne Scott - Poway CA, US
Timothy P. Tully - Solana Beach CA, US

Assignee:

Helicon Therapeutics, Inc. - San Diego CA

International Classification:

A61K 31/70
C07H 21/04

US Classification:

514 44, 536 245

Abstract:

The present invention provides methods for screening a pharmaceutical agent for its ability to modulate long term memory formation, performance of a hippocampal-dependent cognitive task or Gpr12 function. The present invention also provides methods for modulating long term memory formation or performance of a hippocampal-dependent cognitive task by modulating Gpr12-dependent protein expression. The present invention further provides methods for treating a defect in long term memory formation by inhibiting Gpr12 function and methods for treating a defect in performance of a hippocampal-dependent cognitive task by inhibiting Gpr12 function.

US Patent:

20090053140, Feb 26, 2009

Filed:

May 15, 2008

Appl. No.:

12/121742

Inventors:

Roderick Euan Milne Scott - Poway CA, US
Rusiko Bourtchouladze - New York NY, US
Marco Peters - La Jolla CA, US
Timothy P. Tully - Solana Beach CA, US

International Classification:

A61K 49/00

US Classification:

424 91

Abstract:

The present invention relates to a method of identifying a gene or gene product associated with transcription dependent memory formation in an animal comprising the steps of: (a) administering to said animal sufficient small interfering RNA (siRNA) specific for the gene to inhibit gene function; (b) training said animal under conditions sufficient to induce transcription dependent memory formation in a normal untreated animal; and (c) determining the level of transcription dependent memory formation induced by the training of the treated animal. The present invention provides methods of using small interfering PNAs (siRNA) in hippocampus to identify genes and gene product whose inhibition affects contextual and temporal long-term (LTM) memory, but not short-term memory (STM).

US Patent:

20100285990, Nov 11, 2010

Filed:

Dec 29, 2008

Appl. No.:

12/810617

Inventors:

Timothy P. Tully - Solana Beach CA, US
Marco Peters - La Jolla CA, US
Roderick E. Scott - Poway CA, US

International Classification:

C40B 30/06
C40B 30/00

US Classification:

506 10, 506 7

Abstract:

The disclosed invention relates to cell based screening assays that are useful to identify compounds that enhance memory in normal and memory impaired individuals.

US Patent:

20110281936, Nov 17, 2011

Filed:

Jun 27, 2011

Appl. No.:

13/169739

Inventors:

Marco Peters - La Jolla CA, US
Roderick Euan Milne Scott - Poway CA, US
Timothy P. Tully - Solana Beach CA, US

International Classification:

A61K 31/713
A61P 25/00
C12Q 1/68

US Classification:

514 44 A, 435 612

Abstract:

The present invention provides methods for screening a pharmaceutical agent for its ability to modulate long term memory formation, performance of a hippocampal-dependent cognitive task or Gpr12 function. The present invention also provides methods for modulating long term memory formation or performance of a hippocampal-dependent cognitive task by modulating Gpr12-dependent protein expression. The present invention further provides methods for treating a defect in long term memory formation by inhibiting Gpr12 function and methods for treating a defect in performance of a hippocampal-dependent cognitive task by inhibiting Gpr12 function.

US Patent:

20210340127, Nov 4, 2021

Filed:

Feb 26, 2019

Appl. No.:

16/976363

Inventors:

- Dallas TX, US
Brett C. Bookser - San Diego CA, US
Scott Burley - Oceanside CA, US
Andrew Hudson - San Diego CA, US
Marco Peters - Fallbrook CA, US
Benjamin Pratt - Encinitas CA, US
Aaron Thompson - San Diego CA, US
Joe Tran - San Marcos CA, US
Lino Valdez - San Diego CA, US

International Classification:

C07D 405/12
A61P 25/28
C07D 309/14
C07C 211/40
C07C 237/24
C07C 255/46
C07D 213/38
C07D 401/12
C07D 211/96
C07D 211/58
C07D 207/14
C07D 211/76
C07D 207/273

Abstract:

Substituted cyclohexyl chemical entities of Formula (I): wherein R, G, and Rhave any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive therapies; modulating and treating disorders mediated by nociceptin activity or dopamine signaling; treating neurological disorders, neurodegenerative diseases, depression, and schizophrenia; enhancing the efficiency of cognitive and motor training; and treating peripheral disorders, including renal, respiratory, gastrointestinal, liver, genitourinary, metabolic, and inflammatory disorders.

US Patent:

20190046535, Feb 14, 2019

Filed:

Oct 18, 2018

Appl. No.:

16/164726

Inventors:

- Grand Cayman, KY
James Breitenbucher - Escondido CA, US
Brian Dyck - San Diego CA, US
Laurent Gomez - San Diego CA, US
Andrew Richard Hudson - San Diego CA, US
Tami Jo Marrone - Carlsbad CA, US
Marco Peters - San Diego CA, US
Troy Vickers - San Diego CA, US
Michael I. Weinhouse - Escondido CA, US

International Classification:

A61K 31/519
C07D 495/14
C07D 519/00
C07D 495/22
C07D 491/147
C07D 491/107
C07D 491/22
C07D 498/08
C07D 471/14
C07D 495/12
C07D 487/14
A61K 31/5377
A61K 31/541
A61K 31/5386
A61K 31/553
A61K 31/551
A61K 31/55

Abstract:

Described herein are compounds of Formula I and Formula II, methods of their synthesis, compositions comprising the compounds, and use of the compounds and compositions in treating numerous diseases and disorders, including cognitive deficits associated with CNS diseases and disorders.

US Patent:

20170209459, Jul 27, 2017

Filed:

Nov 17, 2016

Appl. No.:

15/354804

Inventors:

- Grand Cayman, KY
James Breitenbucher - Escondido CA, US
Brian Dyck - San Diego CA, US
Laurent Gomez - San Diego CA, US
Andrew Richard Hudson - San Diego CA, US
Tami Jo Marrone - Carlsbad CA, US
Marco Peters - San Diego CA, US
Troy Vickers - San Diego CA, US

International Classification:

A61K 31/553
A61K 31/541
A61K 31/55
A61K 31/551
A61K 31/519
A61K 31/5377

Abstract:

Described herein are compounds and chemical entities of Formula I, methods of their synthesis, compositions comprising them, and their use in treating numerous diseases and disorders, including cognitive deficits associated with CNS diseases and disorders.

US Patent:

20170182052, Jun 29, 2017

Filed:

Dec 29, 2016

Appl. No.:

15/394058

Inventors:

- Grand Gayman, KY
James Breitenbucher - Escondido CA, US
Brian Dyck - San Diego CA, US
Laurent Gomez - San Diego CA, US
Andrew Richard Hudson - San Diego CA, US
Tami Jo Marrone - Carlsbad CA, US
Marco Peters - San Diego CA, US
Troy Vickers - San Diego CA, US
Michael Weinhouse - Escondido CA, US

International Classification:

A61K 31/519
A61K 31/551
A61K 31/5386
A61K 31/55
A61K 31/553
A61K 31/5377

Abstract:

Described herein are compounds of Formula I and Formula II, methods of their synthesis, compositions comprising the compounds, and use of the compounds and compositions in treating numerous diseases and disorders, including cognitive deficits associated with CNS diseases and disorders.